Verastem, Inc. (VSTM)

Over the past six months, Verastem's stock price has experienced fluctuations. In October 2025, Verastem's shares dropped following GenFleet's presentation of updated clinical data for GFH375. In May 2025, the company transitioned to a commercial-stage entity with the FDA approval and launch of AVMAPKI FAKZYNJA CO-PACK. In January 2026, outstanding cash warrants were exercised, netting $29.4 million for the company. In March 2026, Verastem provided preliminary fourth-quarter and full-year 2025 revenue and business updates, outlining 2026 strategic priorities.

As a biopharmaceutical company focused on developing and commercializing medicines for cancer, the demand for Verastem, Inc.'s products and services is generally not subject to significant seasonality. Demand for cancer treatments is primarily driven by disease incidence, diagnosis rates, and evolving treatment guidelines, rather than seasonal factors.

Verastem, Inc., also known as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines for RAS/MAPK pathway-driven cancers. The company's main product is AVMAPKI FAKZYNJA CO-PACK, approved in the U.S. for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer. Verastem's pipeline includes small molecule drugs that inhibit critical signaling pathways in cancer, such as RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition.

Verastem, Inc. is headquartered in Needham, Massachusetts, and incorporated in Delaware. While its primary focus is in the U.S., the company is pursuing regulatory paths for potential geographic expansion into Europe and Japan. Verastem is also conducting international clinical trials, indicating a global reach for its clinical development programs.

Verastem's brand reputation has been shaped by positive developments and clinical trial outcomes. The company generally holds a positive reputation among analysts, with a consensus "Buy" rating. The FDA approval of AVMAPKI FAKZYNJA CO-PACK and the subsequent transition to a commercial-stage company significantly boosted its standing. A presentation of updated clinical data for VS-7375 by GenFleet at the ESMO meeting showed numerically lower efficacy compared to previous data, leading to a 13% drop in stock price. Continued positive updates on its clinical pipeline contribute positively to its reputation.

Approximately 61.17% of Verastem's stock is owned by Institutional Investors, 1.17% by Insiders, and 37.66% by Public Companies and Individual Investors. Major institutional owners include RTW Investments, LP, Deep Track Capital, LP, and BlackRock, Inc.